Dianthus Therapeutics, Inc. (DNTH)

Dianthus Therapeutics' stock has experienced notable movements in the past six months. Over the last 12 months, the stock price increased, but it decreased in the past month as of January 14, 2026. Following its earnings report on November 5, 2025, DNTH shares gained 8.0% the next day, closing at $36.43. Since that earnings announcement, the stock has drifted 4.8% higher and traded within a range of $34.29 and $45.46. On January 14, 2026, the stock reached a new 52-week high of $46.22, closing at $44.86. Analyst ratings for DNTH are generally positive, with a consensus of "Strong Buy" or "Moderate Buy" and price targets suggesting significant upside potential. However, there was a report of the CFO selling shares, and the company's stock entered oversold territory. Additionally, short interest in Dianthus Therapeutics recently increased by 47.36%, which could indicate a decrease in investor sentiment.

Information regarding demand seasonality for Dianthus Therapeutics, Inc.'s products and services is not explicitly detailed in the provided search results. As a clinical-stage biotechnology company with its lead product candidate, DNTH103, currently in clinical trials, traditional demand seasonality, as seen in consumer goods, is not directly applicable. The company's progress and financial performance are more likely influenced by clinical trial milestones, regulatory approvals, and funding cycles rather than seasonal consumer demand. Seeking Alpha does offer tools to display mean and median monthly returns for DNTH to identify seasonal patterns, but access to these specific patterns requires an account.

Dianthus Therapeutics, Inc. (DNTH) is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune and inflammatory diseases, operating within the Healthcare sector, specifically in the Biotechnology & Medical Research industry. Their lead product candidate, DNTH103 (claseprubart), is in clinical trials for generalized Myasthenia Gravis (gMG), multifocal motor neuropathy (MMN), and chronic inflammatory demyelinating polyneuropathy (CIDP). Dianthus Therapeutics also has an investigational bifunctional fusion protein, DNTH212, in its pipeline.

Dianthus Therapeutics, Inc. is headquartered in New York, NY, and has offices in Waltham, MA. Clinical trials for DNTH103 are conducted globally.

Dianthus Therapeutics has maintained a largely positive brand reputation in the past year, particularly among analysts. Analyst sentiment was overwhelmingly positive as of January 9, 2026, with 14 buy ratings and no hold or sell recommendations. The average rating for DNTH stock is a "Strong Buy" from 9 analysts, with a 12-month stock price target of $68.88, indicating an 80.36% upside. The consensus rating is a "Moderate Buy," based on 8 buy ratings and 1 sell rating. Key events contributing to its reputation include the reporting of positive Phase 2 data for DNTH103 in generalized Myasthenia Gravis (gMG) in September 2025, which was also presented at the American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting. The company also participated in the 44th Annual J.P. Morgan Healthcare Conference in January 2026, where its CEO presented a corporate overview. While the increase in short interest could be seen as a negative sentiment indicator, no specific negative events significantly impacting the company's overall brand reputation were found in the past year.

Dianthus Therapeutics, Inc. is primarily owned by institutional shareholders, who hold 109.22% of the stock, and insiders, holding 78.53%. Retail investors hold 0.00%. The company has 278 institutional owners and shareholders, collectively holding 48,924,030 shares. Major institutional shareholders include Fmr LLC, Fairmount Funds Management LLC, Avidity Partners Management LP, Ra Capital Management, L.p., Wellington Management Group Llp, Octagon Capital Advisors LP, Point72 Asset Management, L.P., TCG Crossover Management, LLC, Vanguard Group Inc, and BlackRock, Inc. Fairmount Funds Management LLC is also identified as the largest individual shareholder, owning 8.16 million shares, representing 19.04% of the company. The majority of the company's shareholders are from the United States, accounting for 91.9% of the geographical origin of shareholders.